This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lilly To Present Phase II Rheumatoid Arthritis And Biomarker Data At ACR For Two Investigational Medicines To Treat Autoimmune Diseases

INDIANAPOLIS, Nov. 9, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology (ACR), which takes place Nov. 10-14, 2012, in Washington, D.C. These compounds include tabalumab, an anti-BAFF monoclonal antibody, and baricitinib, a janus kinase (JAK) inhibitor being developed in partnership with Incyte Corporation.

The abstracts showcase Lilly's data for baricitinib and tabalumab in RA across a number of areas, including efficacy and safety data, a magnetic resonance imaging (MRI) sub-study examining joint changes, patient-reported outcomes and data on novel molecular markers.

"So many people with autoimmune diseases such as rheumatoid arthritis have significant medical needs for additional treatment options, and Lilly is committed to developing potential treatments to address those needs," said Eiry Roberts, M.D., vice president of autoimmune product development at Lilly. "We believe the collection of data presented at ACR highlights our progress in the autoimmune space, along with the approach and strength of Lilly's autoimmune pipeline."

Studies, as well as the times and locations of the data sessions, are highlighted below.

Baricitinib (LY3009104, formerly INCB28050)

  • Abstract #490: Poster Session: Sunday, Nov. 11, 9 a.m.-6 p.m. ET
    • 12- and 24-Week Patient-Reported Outcomes from a Phase IIb Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1 / Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    • Presenter: Josef S. Smolen, Medical University of Vienna and Hietzing Hospital
    • Location: Poster Hall B
  • Abstract #2487: Oral Session: Tuesday, Nov. 13, 3 p.m. ET
    • 24-Week Results of a Blinded Phase IIb Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1 / Janus Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    • Presenter: Mark C. Genovese, Stanford University Medical Center
    • Location: Ballroom C
  • Abstract #2488: Oral Session: Tuesday, Nov. 13, 3:15 p.m. ET
    • Magnetic Resonance Imaging Substudy in a Phase IIb Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1 / Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    • Presenter: Charles G. Peterfy, Spire Sciences LLC
    • Location: Ballroom C
  • Abstract #2653: Oral Session: Wednesday, Nov. 14, 11 a.m. ET
    • A Subset of up-Regulated IFN Regulated Genes in CANDLE Patients Decrease with Treatment with a JAK Inhibitor
    • Presenter: Adriana Almeida de Jesus, National Institute of Arthritis Musculoskeletal and Skin Disease, National Institutes of Health
    • Location: 143 A

Tabalumab (LY2127399):

  • Abstract #447: Poster Session: Sunday, Nov. 11, 9 a.m.-6 p.m. ET
    • Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study
    • Presenter: Maria W. Greenwald, Desert Medical Advances
    • Location: Poster Hall B
  • Abstract #1276: Poster Session: Monday, Nov. 12, 9 a.m.-6 p.m. ET
    • Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab
    • Presenter: Maria W. Greenwald, Desert Medical Advances
    • Location: Poster Hall B
  • Abstract #1315: Poster Session: Monday, Nov. 12, 9 a.m.-6 p.m. ET
    • Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
    • Presenter: Wendy J. Komocsar, Eli Lilly and Company
    • Location: Poster Hall B

About JAK Inhibition and Baricitinib There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. These enzymes are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA patients. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through the JAK/STAT pathways. Additional JAK-dependent cytokines also have been implicated in a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions.

Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor that spares JAK3. Baricitinib is advancing into Phase III development as a potential treatment for rheumatoid arthritis and it is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy. In December 2009, Lilly and Incyte announced an agreement for the development and commercialization of baricitinib and certain follow-on compounds for inflammatory and autoimmune diseases.

About BAFF and Tabalumab  BAFF (B cell activating factor) is a cytokine that promotes B cell survival, proliferation and activation. In the presence of excess BAFF, B cells, including autoreactive B cells, are not appropriately eliminated by the immune system and may therefore contribute to the development of RA by producing autoantibodies and proinflammatory cytokines and "helping" autoreactive T cells. BAFF exists in both membrane-bound and soluble forms.

Tabalumab is a human immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that inhibits both membrane-bound and soluble B cell activating factor (BAFF). Tabalumab is currently in Phase III development as a potential treatment for rheumatoid arthritis and lupus.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs